Synthesis, Kinetic and Conformational Studies of 2-Substituted-5-(β-d-glucopyranosyl)-pyrimidin-4-ones as Potential Inhibitors of Glycogen Phosphorylase.
Animals
Catalytic Domain
Computational Biology
Drug Design
Enzyme Inhibitors
/ chemical synthesis
Glucose
/ chemistry
Glycogen Phosphorylase, Muscle Form
/ antagonists & inhibitors
Kinetics
Molecular Conformation
Molecular Docking Simulation
Muscle, Skeletal
/ enzymology
Pyrimidinones
/ chemical synthesis
Rabbits
5-(β-d-glucopyranosyl)pyrimidin-4-one synthesis
DFT conformational analysis
cancer
catalytic site inhibitors
glycogen phosphorylase
type 2 diabetes
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
22 Nov 2020
22 Nov 2020
Historique:
received:
20
10
2020
revised:
16
11
2020
accepted:
19
11
2020
entrez:
3
12
2020
pubmed:
4
12
2020
medline:
30
3
2021
Statut:
epublish
Résumé
Dysregulation of glycogen phosphorylase, an enzyme involved in glucose homeostasis, may lead to a number of pathological states such as type 2 diabetes and cancer, making it an important molecular target for the development of new forms of pharmaceutical intervention. Based on our previous work on the design and synthesis of 4-arylamino-1-(β-d-glucopyranosyl)pyrimidin-2-ones, which inhibit the activity of glycogen phosphorylase by binding at its catalytic site, we report herein a general synthesis of 2-substituted-5-(β-d-glucopyranosyl)pyrimidin-4-ones, a related class of metabolically stable,
Identifiants
pubmed: 33266408
pii: molecules25225463
doi: 10.3390/molecules25225463
pmc: PMC7700572
pii:
doi:
Substances chimiques
Enzyme Inhibitors
0
Pyrimidinones
0
Glycogen Phosphorylase, Muscle Form
EC 2.4.1.-
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : State Scholarships Foundation
ID : 5432
Références
Mini Rev Med Chem. 2010 Oct;10(12):1188-93
pubmed: 20716050
Bioorg Med Chem Lett. 2012 Jun 15;22(12):4127-32
pubmed: 22578461
J Mol Med (Berl). 2016 Feb;94(2):137-54
pubmed: 26882899
Drugs. 2017 Sep;77(14):1577-1592
pubmed: 28836175
J Exp Pharmacol. 2020 Jan 10;12:1-15
pubmed: 32021494
Biochem Biophys Res Commun. 2003 Sep 12;309(1):126-34
pubmed: 12943673
Chem Rev. 2017 Oct 11;117(19):12281-12356
pubmed: 28915018
Chemistry. 2017 Jul 3;23(37):8800-8805
pubmed: 28493496
Phys Chem Chem Phys. 2019 Apr 3;21(14):7685-7696
pubmed: 30912774
Molecules. 2020 Feb 06;25(3):
pubmed: 32041285
ACS Med Chem Lett. 2015 Oct 19;6(12):1215-9
pubmed: 26713107
Chem Rev. 2017 Feb 8;117(3):1687-1764
pubmed: 28121130
J Biol Chem. 2018 May 11;293(19):7108-7116
pubmed: 29572349
Curr Pharm Des. 2003;9(15):1177-89
pubmed: 12769745
Cell Metab. 2012 Dec 5;16(6):751-64
pubmed: 23177934
Protein Sci. 1995 Dec;4(12):2469-77
pubmed: 8580837
Cancer Res. 1984 Jan;44(1):154-60
pubmed: 6418376
Mol Cell Proteomics. 2005 Dec;4(12):1920-32
pubmed: 16127175
Curr Med Chem. 2008;15(28):2933-83
pubmed: 19075645
Expert Opin Ther Pat. 2016;26(2):199-212
pubmed: 26666989
Curr Opin Investig Drugs. 2008 Apr;9(4):379-95
pubmed: 18393105
Metab Brain Dis. 2015 Feb;30(1):251-3
pubmed: 25060966
Biochem Pharmacol. 2014 Nov 1;92(1):3-11
pubmed: 25219323
Mini Rev Med Chem. 2010 Oct;10(12):1127-38
pubmed: 20716054
J Am Chem Soc. 1948 May;70(5):1753-6
pubmed: 18861762
Mini Rev Med Chem. 2010 Oct;10(12):1102-26
pubmed: 20716051
FEBS Lett. 2010 Oct 22;584(20):4366-72
pubmed: 20888814
Cancer Res. 1981 Mar;41(3):1165-70
pubmed: 7459858
Anal Biochem. 1985 Aug 1;148(2):277-81
pubmed: 4061809
Eur J Med Chem. 2016 Nov 10;123:737-745
pubmed: 27522507
Org Lett. 2011 Jul 15;13(14):3628-31
pubmed: 21671612
Cancer Res. 1979 Feb;39(2 Pt 1):531-4
pubmed: 761227
Curr Med Chem. 2011;18(17):2620-9
pubmed: 21568887
Org Lett. 2006 Aug 17;8(17):3737-40
pubmed: 16898805
Org Lett. 2006 Aug 31;8(18):4121-4
pubmed: 16928089
Cell Metab. 2012 Dec 5;16(6):687-8
pubmed: 23217251
Expert Opin Investig Drugs. 2001 Mar;10(3):439-54
pubmed: 11227044
Carbohydr Res. 1999 Jul 20;320(1-2):19-30
pubmed: 10515061